185 related articles for article (PubMed ID: 18232633)
1. Novel inhibitors of the Gardos channel for the treatment of sickle cell disease.
McNaughton-Smith GA; Burns JF; Stocker JW; Rigdon GC; Creech C; Arrington S; Shelton T; de Franceschi L
J Med Chem; 2008 Feb; 51(4):976-82. PubMed ID: 18232633
[TBL] [Abstract][Full Text] [Related]
2. ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice.
Stocker JW; De Franceschi L; McNaughton-Smith GA; Corrocher R; Beuzard Y; Brugnara C
Blood; 2003 Mar; 101(6):2412-8. PubMed ID: 12433690
[TBL] [Abstract][Full Text] [Related]
3. [Clinical trials of new therapeutic pharmacology for sickle cell disease].
Brugnara C; de Franceschi L
Sante; 2006; 16(4):263-8. PubMed ID: 17446160
[TBL] [Abstract][Full Text] [Related]
4. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043).
Ataga KI; Reid M; Ballas SK; Yasin Z; Bigelow C; James LS; Smith WR; Galacteros F; Kutlar A; Hull JH; Stocker JW;
Br J Haematol; 2011 Apr; 153(1):92-104. PubMed ID: 21323872
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Ca(2+)-dependent K+ transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives.
Brugnara C; de Franceschi L; Alper SL
J Clin Invest; 1993 Jul; 92(1):520-6. PubMed ID: 8326017
[TBL] [Abstract][Full Text] [Related]
6. Potent antagonists of the Kv1.5 potassium channel: synthesis and evaluation of analogous N,N-diisopropyl-2-(pyridine-3-yl)acetamides.
Nanda KK; Nolt MB; Cato MJ; Kane SA; Kiss L; Spencer RH; Wang J; Lynch JJ; Regan CP; Stump GL; Li B; White R; Yeh S; Bogusky MJ; Bilodeau MT; Dinsmore CJ; Lindsley CW; Hartman GD; Wolkenberg SE; Trotter BW
Bioorg Med Chem Lett; 2006 Nov; 16(22):5897-901. PubMed ID: 16949818
[TBL] [Abstract][Full Text] [Related]
7. Abnormal permeability pathways in human red blood cells.
Ellory JC; Robinson HC; Browning JA; Stewart GW; Gehl KA; Gibson JS
Blood Cells Mol Dis; 2007; 39(1):1-6. PubMed ID: 17434766
[TBL] [Abstract][Full Text] [Related]
8. Selective intermediate-/small-conductance calcium-activated potassium channel (KCNN4) blockers are potent and effective therapeutics in experimental brain oedema and traumatic brain injury caused by acute subdural haematoma.
Mauler F; Hinz V; Horváth E; Schuhmacher J; Hofmann HA; Wirtz S; Hahn MG; Urbahns K
Eur J Neurosci; 2004 Oct; 20(7):1761-8. PubMed ID: 15379997
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological inhibition of calpain-1 prevents red cell dehydration and reduces Gardos channel activity in a mouse model of sickle cell disease.
De Franceschi L; Franco RS; Bertoldi M; Brugnara C; Matté A; Siciliano A; Wieschhaus AJ; Chishti AH; Joiner CH
FASEB J; 2013 Feb; 27(2):750-9. PubMed ID: 23085996
[TBL] [Abstract][Full Text] [Related]
10. Pharmacophore-based search, synthesis, and biological evaluation of anthranilic amides as novel blockers of the Kv1.5 channel.
Peukert S; Brendel J; Pirard B; Strübing C; Kleemann HW; Böhme T; Hemmerle H
Bioorg Med Chem Lett; 2004 Jun; 14(11):2823-7. PubMed ID: 15125940
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the potassium channel K
Staal RGW; Khayrullina T; Zhang H; Davis S; Fallon SM; Cajina M; Nattini ME; Hu A; Zhou H; Poda SB; Zorn S; Chandrasena G; Dale E; Cambpell B; Biilmann Rønn LC; Munro G; Mӧller T
Eur J Pharmacol; 2017 Jan; 795():1-7. PubMed ID: 27876619
[TBL] [Abstract][Full Text] [Related]
12. Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia.
Ataga KI; Stocker J
Expert Opin Investig Drugs; 2009 Feb; 18(2):231-9. PubMed ID: 19236269
[TBL] [Abstract][Full Text] [Related]
13. Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease.
Brugnara C; Gee B; Armsby CC; Kurth S; Sakamoto M; Rifai N; Alper SL; Platt OS
J Clin Invest; 1996 Mar; 97(5):1227-34. PubMed ID: 8636434
[TBL] [Abstract][Full Text] [Related]
14. Oral administration of clotrimazole and blockade of human erythrocyte Ca(++)-activated K+ channel: the imidazole ring is not required for inhibitory activity.
Brugnara C; Armsby CC; Sakamoto M; Rifai N; Alper SL; Platt O
J Pharmacol Exp Ther; 1995 Apr; 273(1):266-72. PubMed ID: 7714775
[TBL] [Abstract][Full Text] [Related]
15. IKCa-channel blockers. Part 2: discovery of cyclohexadienes.
Urbahns K; Goldmann S; Krüger J; Horváth E; Schuhmacher J; Grosser R; Hinz V; Mauler F
Bioorg Med Chem Lett; 2005 Jan; 15(2):401-4. PubMed ID: 15603962
[TBL] [Abstract][Full Text] [Related]
16. Erythrocytes from hereditary xerocytosis patients heterozygous for KCNN4 V282M exhibit increased spontaneous Gardos channel-like activity inhibited by senicapoc.
Rivera A; Vandorpe DH; Shmukler BE; Gallagher DR; Fikry CC; Kuypers FA; Brugnara C; Snyder LM; Alper SL
Am J Hematol; 2017 Jun; 92(6):E108-E110. PubMed ID: 28295477
[No Abstract] [Full Text] [Related]
17. Pharmacology of the human red cell voltage-dependent cation channel; Part I. Activation by clotrimazole and analogues.
Barksmann TL; Kristensen BI; Christophersen P; Bennekou P
Blood Cells Mol Dis; 2004; 32(3):384-8. PubMed ID: 15121096
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants.
Pegoraro S; Lang M; Dreker T; Kraus J; Hamm S; Meere C; Feurle J; Tasler S; Prütting S; Kuras Z; Visan V; Grissmer S
Bioorg Med Chem Lett; 2009 Apr; 19(8):2299-304. PubMed ID: 19282171
[TBL] [Abstract][Full Text] [Related]
19. The Clinically Tested Gardos Channel Inhibitor Senicapoc Exhibits Antimalarial Activity.
Tubman VN; Mejia P; Shmukler BE; Bei AK; Alper SL; Mitchell JR; Brugnara C; Duraisingh MT
Antimicrob Agents Chemother; 2016 Jan; 60(1):613-6. PubMed ID: 26459896
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia.
Ataga KI; Smith WR; De Castro LM; Swerdlow P; Saunthararajah Y; Castro O; Vichinsky E; Kutlar A; Orringer EP; Rigdon GC; Stocker JW;
Blood; 2008 Apr; 111(8):3991-7. PubMed ID: 18192510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
